阿苯达唑和咯萘啶对绵羊细粒棘球蚴病的疗效评估

doi:10.12140/j.issn.1000-7423.2025.06.006

中国寄生虫学与寄生虫病杂志 ›› 2025, Vol. 43 ›› Issue (6): 786-792.doi: 10.12140/j.issn.1000-7423.2025.06.006

阿苯达唑和咯萘啶对绵羊细粒棘球蚴病的疗效评估

颜明智¹^,²(), 张耀¹^,³, 齐文静¹^,², 王雪², 张国武¹, 吴川川², 田梦潇², 耿谙², 王味思⁴, 段李平⁴, 宋涛⁵, 游锡火⁶, 李军¹, 张文宝¹^,^*()()

¹ 省部共建中亚高发病成因与防治国家重点实验室，新疆医科大学第一附属医院临床医学研究院，新疆乌鲁木齐 830054
² 新疆医科大学基础医学院，新疆乌鲁木齐 830017
³ 厦门大学生命科学学院寄生动物研究室，福建厦门 361100
⁴ 中国疾病预防控制中心寄生虫病预防控制所（国家热带病研究中心），上海 200025
⁵ 新疆医科大学第一附属医院腹部超声诊断科，新疆乌鲁木齐 830054
⁶ 中农华威生物制药（湖北）有限公司，湖北黄冈 436300

收稿日期:2025-05-29 修回日期:2025-07-26 出版日期:2025-12-30 发布日期:2025-12-30
通讯作者: *张文宝（ORCID：0000-0002-3110-1600），男，博士，研究员，从事人兽共患病防治。E-mail：wenbaozhang2013@163.com
作者简介:颜明智，男，硕士，实验师，从事人兽共患病防治。E-mail：451417137@qq.com
基金资助:
新疆维吾尔自治区“天山英才”培养计划-科技创新团队项目(2023TSYCTD0017);国家重点研发计划(2023YFD1801204-2);省部共建中亚高发病成因与防治国家重点实验室开放课题(SKL-HIDCA-2023-34);新疆医科大学第一附属医院“青年科研起航”专项基金(2023YFY-QKQN-49)

Therapeutic efficacy of albendazole and pyronaridine for the treatment of cystic echinococcosis in sheep

YAN Mingzhi¹^,²(), ZHANG Yao¹^,³, QI Wenjing¹^,², WANG Xue², ZHANG Guowu¹, WU Chuanchuan², TIAN Mengxiao², GENG An², WANG Weisi⁴, DUAN Liping⁴, SONG Tao⁵, YOU Xihuo⁶, LI Jun¹, ZHANG Wenbao¹^,^*()()

¹ State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medicine Institute, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
² School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830054, China
³ Research Laboratory of Parasitic Animals, School of Life Sciences, Xiamen University, Xiamen 361100, China
⁴ National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Chinese Center for Tropical Diseases Research, Shanghai 200025, China
⁵ Department of Abdominal Ultrasonography, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
⁶ Zhongnong Huawei Biopharmaceutical (Hubei) Co., Ltd., Huanggang 436300, Hubei, China

Received:2025-05-29 Revised:2025-07-26 Online:2025-12-30 Published:2025-12-30
Contact: *E-mail：wenbaozhang2013@163.com
Supported by:
Xinjiang Science and Technology Department’s “Tianshan Talent” Training Program - Science and Technology Innovation Team Project(2023TSYCTD0017);National Key Research and Development Program of China(2023YFD1801204-2);State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases Fund(SKL-HIDCA-2023-34);Special Fund for “Young Research Starter” of the First Affiliated Hospital of Xinjiang Medical University(2023YFY-QKQN-49)

摘要/Abstract

摘要：

目的评估阿苯达唑（ABZ）和咯萘啶（PND）治疗绵羊细粒棘球蚴病（CE）的效果。方法对来源于新疆维吾尔自治区天山中部山区的绵羊进行B超影像学检查，筛选出18只具有典型CE特征且感染情况相近的绵羊。采用完全随机分组设计将18只CE绵羊随机分为对照组、ABZ组和PND组3组，ABZ组饲喂含ABZ的饲料诱饵（每1 g饲料诱饵含0.4 g ABZ），PND组饲喂含PND的饲料诱饵（每1 g饲料诱饵含0.2 g PND），对照组饲喂不含药物的饲料诱饵，连续给药30 d，停药后继续饲养30 d。分别于给药前和停药30 d后对CE绵羊实施全肝系统性扫描，记录包囊大小。停药30 d后获取绵羊心、肝、脾、肺、肾等脏器并称重，采集绵羊全血样品检测血常规和血生化指标。分离肝脏包囊，根据包囊外观和内容物将包囊分为可育包囊、不育包囊和钙化包囊，记录不同包囊的数量并称重。将肝组织制成石蜡切片，苏木精-伊红（HE）染色观察病理变化并进行炎性细胞浸润评分。采用IBM SPSS Statistics 20软件进行统计分析。采用单因素方差分析或非参数检验进行多重比较，包囊类型的组间比较采用卡方检验。结果 B超结果显示，给药前，对照组、ABZ组和PND组的包囊直径分别为（2.86 ± 0.94）、（2.58 ± 0.83）和（2.65 ± 0.81） cm，差异无统计学意义（F = 0.090，P > 0.05）；停药30 d后，ABZ组和PND组的包囊直径分别为（0.41 ± 0.30）和（0.85 ± 0.24） cm，明显低于对照组的（3.03 ± 0.42） cm（F = 110.398，P < 0.01）。停药30 d后，对照组、ABZ组和PND组绵羊的肝质量分别为（0.98 ± 0.20）、（0.74 ± 0.16）和（0.61 ± 0.30） kg，差异有统计学意义（F = 3.989，P < 0.05）。对照组、ABZ组和PND组绵羊的血常规和血生化各项指标差异均无统计学意义（均P > 0.05）。停药30 d后，ABZ组和PND组的包囊总质量分别为（0.02 ± 0.05）和（0.05 ± 0.08） kg，明显低于对照组的（0.17 ± 0.06） kg（F = 7.835，P < 0.01）。对照组中可育包囊、不育包囊和钙化包囊分别占63.16%（48/76）、17.10%（13/76）和19.74%（15/76），ABZ组中3种包囊分别占23.08%（12/52）、1.92%（1/52）和75.00%（39/52），两组的差异有统计学意义（χ² = 39.439，P < 0.01），其中ABZ组的可育包囊率和不育包囊率均降低，钙化包囊率升高；PND组可育包囊、不育包囊和钙化包囊分别占31.03%（18/58）、6.90%（4/58）和62.07%（36/58），与对照组的差异有统计学意义（χ² = 25.083，P < 0.01），其中PND组的可育包囊率降低、钙化包囊率升高。停药30 d后，ABZ组和PND组的炎性细胞浸润评分分别为1.06 ± 0.25和1.50 ± 0.28，均低于对照组的2.72 ± 0.44（F = 39.780，P < 0.01）。结论口服ABZ和PND均能够降低CE绵羊肝包囊中可育包囊的数量、减轻炎性细胞浸润程度，对绵羊CE有一定治疗效果。

关键词: 细粒棘球蚴病, 绵羊, 咯萘啶, 阿苯达唑, 药物治疗

Abstract:

Objective To evaluate the efficacy of albendazole (ABZ) and pyronaridine (PND) for the treatment of cystic echinococcosis (CE) in sheep. Methods B-mode ultrasonography was performed in sheep from the central Tianshan Mountains regions in Xinjiang Uygur Autonomous Region, and 18 sheep with typical CE characteristics and comparable prevalence were selected, and randomized into the control group, the ABZ group and PND group using a completely randomized design. Sheep in the ABZ group were fed baits containing ABZ (0.4 g ABZ in 1 g feed bait), and sheep in the PND group were fed baits containing PND (0.2 g PND in 1 g feed bait), while sheep in the control group were fed drug-free feed baits. Drugs were administered continuously for 30 days, followed by a 30-day observation period after drug discontinuation. Whole-liver scans were performed on sheep with CE before dosing and 30 days after drug discontinuation, and cyst size was recorded. Sheep hearts, livers, spleen, lungs, and kidneys were collected and weighed 30 days after drug discontinuation. Whole blood samples were collected for routine blood tests and blood biochemistry analysis. Liver cysts were sampled, and classified into fertile cysts, infertile cysts, and calcified cysts based on the cyst appearance and its contents. The number and weight of different types of cysts were recorded. Hepatic tissues were prepared into paraffin-embedded sections, subjected to hematoxylin-eosin (HE) staining for pathological examinations, and evaluated for scoring of inflammatory cell infiltration. All statistical analyses were performed using the software IBM SPSS Statistics 20. Multiple comparisons were conducted using one-way analysis of variance or nonparametric tests, while intergroup comparisons of cyst types were assessed using chi-square test. Results B-mode ultrasonography measured no significant difference in the diameter of liver cysts among the control group [(2.86 ± 0.94) cm], ABZ group [(2.58 ± 0.83) cm], and PND group [(2.65 ± 0.81) cm] prior to oral administration (F = 0.090, P > 0.05). The diameters of cysts were (0.41 ± 0.30) cm in the ABZ group and (0.85 ± 0.24) cm in the PND group 30 days after drug discontinuation, which were significantly smaller than in the control group [(3.03 ± 0.42) cm] (F = 110.398, P < 0.01). The sheep liver weights were (0.98 ± 0.20), (0.74 ± 0.16), and (0.61 ± 0.30) kg in the control group, ABZ group, and PND group 30 days after drug discontinuation, respectively (F = 3.989, P < 0.05). There were no significant differences in routine blood and biochemical parameters among the control, ABZ, and PND groups (all P > 0.05). The gross cyst weights were (0.02 ± 0.05) kg and (0.05 ± 0.08) kg in the ABZ and PND groups 30 days after drug discontinuation, which were significantly lower than in the control group [(0.17 ± 0.06) kg] (F = 7.835, P < 0.01). The proportions of fertile cysts, infertile cysts, and calcified cysts were 63.16% (48/76), 17.10% (13/76), and 19.74% (15/76) in the control group, and 23.08% (12/52), 1.92% (1/52), and 75.00% (39/52) in the ABZ group, respectively (χ² = 39.439, P < 0.01), with reduced proportions of fertile and infertile cysts and an increased proportion of calcified cysts in the ABZ group. The proportions of fertile cysts, infertile cysts, and calcified cysts were 31.03% (18/58), 6.90% (4/58), and 62.07% (36/58) in the PND group, which showed significant differences relative to the control group (χ² = 25.083, P < 0.01), with an reduced proportion of fertile cysts and an increased proportion of calcified cysts in the PND group. The scores of inflammatory cell infiltration were 1.06 ± 0.25 and 1.50 ± 0.28 in the ABZ and PND groups 30 days after drug discontinuation, which were both significantly lower than in the control group (2.72 ± 0.44) (F = 39.780, P < 0.01). Conclusion Oral administration of ABZ or PND may reduce the number of fertile cysts in livers of sheep with CE and alleviate the severity of inflammatory cell infiltration, indicating that both chemicals are effective against sheep CE.

Key words: Cystic echinococcosis, Sheep, Pyronaridine, Albendazole, Drug therapy

中图分类号:

R532.32

颜明智, 张耀, 齐文静, 王雪, 张国武, 吴川川, 田梦潇, 耿谙, 王味思, 段李平, 宋涛, 游锡火, 李军, 张文宝. 阿苯达唑和咯萘啶对绵羊细粒棘球蚴病的疗效评估[J]. 中国寄生虫学与寄生虫病杂志, 2025, 43(6): 786-792.

YAN Mingzhi, ZHANG Yao, QI Wenjing, WANG Xue, ZHANG Guowu, WU Chuanchuan, TIAN Mengxiao, GENG An, WANG Weisi, DUAN Liping, SONG Tao, YOU Xihuo, LI Jun, ZHANG Wenbao. Therapeutic efficacy of albendazole and pyronaridine for the treatment of cystic echinococcosis in sheep[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2025, 43(6): 786-792.

图/表 3

图1

表1

图2

参考文献 21

[1]	Romig T, Deplazes P, Jenkins D, et al. Ecology and life cycle patterns of Echinococcus species[J]. Adv Parasitol, 2017, 95: 213-314.
[2]	Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: Advances in the 21st century[J]. Clin Microbiol Rev, 2019, 32(2): e00075-18.
[3]	Wang X, Kui Y, Xue CZ, et al. Past, present and future epidemiology of echinococcosis in China based on nationwide surveillance data 2004-2022[J]. J Infect, 2025, 90(3): 106445.
[4]	Borhani M, Fathi S, Harandi MF, et al. Echinococcus granulosus sensu lato control measures: A specific focus on vaccines for both definitive and intermediate hosts[J]. Parasit Vectors, 2024, 17(1): 533.
[5]	Qi XW, Song T, Li Z, et al. Ultrasonography screening of hepatic cystic echinococcosis in sheep flocks used for evaluating control progress in a remote mountain area of Hejing County, Xinjiang[J]. BMC Vet Res, 2024, 20(1): 207.
[6]	Kamali W, Wang SY, Luo WD, et al. Epidemiology and genetic diversity of Echinococcus granulosus sensu stricto in the East Tianshan Mountains, Xinjiang, China[J]. Parasitol Res, 2024, 123(11): 388.
[7]	Horton J. Albendazole for the treatment of echinococcosis[J]. Fundam Clin Pharmacol, 2003, 17(2): 205-212.
[8]	Wiktorowska-Owczarek A, Iacono D, Jasińska-Stroschein M. Editorial: Old drugs: Confronting recent advancements and challenges[J]. Front Pharmacol, 2025, 16: 1565890.
[9]	Li J, Wang WS, Yao JM, et al. Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections[J]. EBioMedicine, 2020, 54: 102711.
[10]	WHO Informal Working Group. International classification of ultrasound images in cystic echinococcosis for application in clinical and field epidemiological settings[J]. Acta Trop, 2003, 85(2): 253-261.
[11]	Zhang HB, Zhao J, Chen B, et al. Pharmacokinetics and tissue distribution study of liposomal albendazole in naturally Echinococcus granulosus infected sheep by a validated UPLC-Q-TOF-MS method[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2020, 1141: 122016.
[12]	Mehmood N, Arshad M, Ahmed H, et al. Comprehensive account on prevalence and characteristics of hydatid cysts in livestock from Pakistan[J]. Korean J Parasitol, 2020, 58(2): 121-127.
[13]	Liu HH, Xie YJ, An XY, et al. Advances in novel diagnostic techniques for alveolar echinococcosis[J]. Diagnostics (Basel), 2025, 15(5): 585.
[14]	Celik F, Simsek S, Ceribasi S, et al. A comparative analysis of ultrasound and serology for the diagnosis and post-treatment monitoring of cystic echinococcosis in experimentally infected sheep[J]. Vet Parasitol, 2025, 334: 110406.
[15]	Golla U, Patel S, Shah N, et al. From deworming to cancer therapy: Benzimidazoles in hematological malignancies[J]. Cancers (Basel), 2024, 16(20): 3454.
[16]	Zheng W, Sun W, Simeonov A. Drug repurposing screens and synergistic drug-combinations for infectious diseases[J]. Br J Pharmacol, 2018, 175(2): 181-191.
[17]	Law GL, Tisoncik-Go J, Korth MJ, et al. Drug repurposing: A better approach for infectious disease drug discovery?[J]. Curr Opin Immunol, 2013, 25(5): 588-592.
[18]	Wang WS, Li J, Qi WJ, et al. Drug repurposing for hard-to-treat human alveolar echinococcosis: Pyronaridine and beyond[J]. Parasitology, 2024, 151(13): 1441-1448.
[19]	Chu WY, Dorlo TPC. Pyronaridine: A review of its clinical pharmacology in the treatment of malaria[J]. J Antimicrob Chemother, 2023, 78(10): 2406-2418.
[20]	Lan QF, Bianba ZM, Mo XJ, et al. Echinococcus infection and metacestode fertility in yaks and sheep - four provincial-level administrative divisions, northwestern China, 2023[J]. China CDC Wkly, 2025, 7(18): 614-619.
[21]	Zhang WB, Zhang ZZ, Yimit T, et al. A pilot study for control of hyperendemic cystic hydatid disease in China[J]. PLoS Negl Trop Dis, 2009, 3(10): e534.

检测指标 Testing criteria	对照组 Control group	ABZ组 ABZ group	PND组 PND group	F值 F value	P值 P value
脏器质量/kg Organ weight/kg
心 Heart	0.21 ± 0.03	0.21 ± 0.02	0.16 ± 0.06	3.638	> 0.05
肝 Liver	0.98 ± 0.20	0.74 ± 0.16	0.61 ± 0.30	3.989	< 0.05
脾 Spleen	0.08 ± 0.01	0.11 ± 0.07	0.07 ± 0.02	1.255	> 0.05
肺 Lung	0.70 ± 0.24	0.61 ± 0.20	0.41 ± 0.22	2.767	> 0.05
肾 Kidney	0.12 ± 0.02	0.07 ± 0.02	0.12 ± 0.03	1.751	> 0.05
血常规 Complete blood count
白细胞/× 10⁹·L^-1 White blood cells/× 10⁹·L^-1	8.53 ± 2.97	7.47 ± 2.28	9.97 ± 2.99	1.237	> 0.05
中性粒细胞/× 10⁹·L^-1 Neutrophils/× 10⁹·L^-1	3.06 ± 1.53	3.13 ± 1.60	3.79 ± 1.49	0.413	> 0.05
淋巴细胞/× 10⁹·L^-1 Lymphocytes/× 10⁹·L^-1	4.76 ± 1.91	3.64 ± 0.70	4.83 ± 1.11	1.502	> 0.05
单核细胞/× 10⁹·L^-1 Monocytes/× 10⁹·L^-1	0.60 ± 0.38	1.05 ± 1.36	0.73 ± 0.32	0.449	> 0.05
嗜酸粒细胞/× 10⁹·L^-1 Eosinophils/× 10⁹·L^-1	0.48 ± 0.17	0.52 ± 0.60	0.56 ± 0.29	0.064	> 0.05
嗜碱粒细胞/× 10⁹·L^-1 Basophils/× 10⁹·L^-1	0.00 ± 0.00	0.00 ± 0.00	0.01 ± 0.01	0.682	> 0.05
红细胞/× 10⁹·L^-1 Red blood cells/× 10⁹·L^-1	9.64 ± 0.43	10.29 ± 0.42	9.57 ± 0.67	3.517	> 0.05
生化指标 Biochemical indicators
丙氨酸氨基转移酶/U·L^-1 Alanine aminotransferase/U·L^-1	34.67 ± 11.88	34.67 ± 10.65	46.67 ± 8.80	2.602	> 0.05
天门冬氨酸氨基转移酶/U·L^-1 Aspartate Aminotransferase/U·L^-1	198.67 ± 51.69	189.67 ± 8.71	198.50 ± 21.78	0.583^a	> 0.05
碱性磷酸酶/U·L^-1 Alkaline phosphatase/U·L^-1	85.83 ± 73.79	120.67 ± 109.03	126.33 ± 118.07	0.277	> 0.05
肌酐/μmol·L^-1 Creatinine/μmol·L^-1	73.67 ± 13.31	76.61 ± 4.56	70.72 ± 9.68	0.536	> 0.05
血尿素氮/mg·dl^-1 Blood Urea Nitrogen/mg·dl^-1	23.83 ± 2.71	25.00 ± 3.58	26.00 ± 4.34	0.543	> 0.05

阿苯达唑和咯萘啶对绵羊细粒棘球蚴病的疗效评估

Therapeutic efficacy of albendazole and pyronaridine for the treatment of cystic echinococcosis in sheep

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	田静, 王晓荣, 伊力亚斯·阿卜杜艾尼, 杨凌菲, 陈璐, 高红英, 周娜, 李玉玲, 崔亮, 宋涛. 基于卷积神经网络的肝细粒棘球蚴病超声分型辅助诊断系统多中心效能研究[J]. 中国寄生虫学与寄生虫病杂志, 2025, 43(5): 619-626.
[2]	刘校伸, 王灏, 杜磊, 樊海宁, 郭新建, 马倩源, 任利. 误诊为胰腺浆液性囊腺瘤的胰腺细粒棘球蚴病1例[J]. 中国寄生虫学与寄生虫病杂志, 2025, 43(1): 152-154.
[3]	孙莉, 卢恩昌, 程猛, 艾艳红. 1例潜伏感染25年肝细粒棘球蚴病报告[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(6): 817-819.
[4]	汪占金, 陈志恒, 李富源, 蔡俊杰, 薛张佗, 周瀛, 曹云太, 王展. 基于影像组学及临床特征的机器学习模型鉴别肝细粒棘球蚴病病灶活性的研究[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(5): 582-593.
[5]	任艳, 宋涛, 尚丰, 吴淼, 王正业, 王晓荣. 卷积神经网络在辅助肝细粒棘球蚴病超声分型诊断的应用[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(4): 454-460.
[6]	候梦丹, 吉古孝安, 刘伟伟, 邱美龄, 胡美荷, 李昆雷, 加依娜尔·吉克散巴依, 翟少华. 绵羊肝细粒棘球蚴包囊形成不同时期的病理学变化观察[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(3): 316-324.
[7]	严信留, 杜尊伟, 杨亚明, 汪丽波, 吴方伟, 李奔福, 李鸿斌, 陈然, 字金荣, 彭佳, 蔡璇, 保雪莹, 唐小英, 杨恒林. 单次和双次阿苯达唑治疗土源性线虫感染的疗效观察[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(2): 204-210.
[8]	蒉嫣, 薛垂召, 王旭, 刘白雪, 王莹, 王立英, 杨诗杰, 韩帅, 许学年. 2022年全国棘球蚴病防治工作进展[J]. 中国寄生虫学与寄生虫病杂志, 2024, 42(1): 8-16.
[9]	马志雅, 谢世臣, 贺渊惠, 高文伟, 刘卿, 朱兴全, 郑文斌. 山西省绵羊捻转血矛线虫的感染现状及遗传变异分析[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(6): 733-738.
[10]	蒉嫣, 薛垂召, 王旭, 刘白雪, 王莹, 王立英, 杨诗杰, 韩帅, 伍卫平, 肖宁. 2021年全国棘球蚴病防治进展[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(2): 142-148.
[11]	路伟民, 杨小涛, 朱瑛, 张鸿, 李霁伟, 王艳春. 儿童肺细粒棘球蚴病1例[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(2): 253-256.
[12]	刘玉婷, 厉广栩. 儿童重型广州管圆线虫病1例[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(6): 813-816.
[13]	郭璐, 吴小霞, 段兰利, 王冰洁, 徐宁, 阿热艾·阿哈太, 乌云花, 赵莉, 班万里, 陈云英, 余婉蓉, 刘帅, 潘星羽, 吾力江·卡马力, 徐晶, 穆尼拉·特列吾汗, 张壮志. 新疆部分地区牛、羊细粒棘球蚴感染情况调查及基因多态性分析[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(5): 603-609.
[14]	秦敏, 王立英. 阿苯达唑联合药物治疗棘球蚴病的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(5): 647-655.
[15]	潘火云, 谭丽梅, 徐翼, 李旭芳, 叶家卫, 房春晓, 杨峰霞, 陈敏霞, 杨花梅, 曾凡森. 12例儿童广州管圆线虫病临床分析[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(5): 668-672.